Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine
Author(s): Catry Emilie, Colsoul Marie-Louise, Closset Melanie, Hubert Justine, Soumoy Laura, Bihin Benoit, Thiry Emmanuell, Jamart Jacques, Hecq Jean-Daniel, Galanti Laurence
Issue: May/Jun 2022 - Volume 26, Number 3
View All Articles in Issue
Page(s): 248-254
Download in electronic PDF format for $75
Abstract: Death rattle, which could often be associated with a pulmonary fluid overload, occurs in 25% to 90% of dying patients. The co-administration of scopolamine (anticholinergic drug) and bumetanide (loop diuretic) could be considered in order to avoid unnecessary fluid overload at end-stage of life. The objective of this study was to investigate the physical and chemical stabilities of the admixture bumetanide and scopolamine in order to prepare them in advance by a centralized intravenous additive service in-hospital pharmacy. The stability of the lowest (LOW) concentration was evaluated on five polypropylene syringes containing the admixture bumetanide (Burinex, 2 mg/4 mL) and scopolamine (0.25 mg/mL) at 41.67 µg/mL and 5.21 µg/mL. The highest (HIGH) concentration with 125 µg/mL of bumetanide and 31.25 µg/mL of scopolamine was evaluated on five polypropylene syringes. All syringes were stored for 18 days at 5°C ± 3°C. Periodic samples were visually and microscopically examined to observe any particle appearance or color change. The pH and absorbance at 3 wavelengths (350 nm, 410 nm, and 550 nm) were monitored. The concentrations were measured by ultra-high performance liquid chromatography–photodiode array detection, using a newly developed method. During the 18 days of test, there was no change in color or appearance of opacity, turbidity, or precipitation, and the pH remained stable. Mean concentrations of bumetanide and scopolamine at LOW and HIGH concentrations after 18 days remained statistically unchanged. The lower limits of the 95% confidence intervals of both molecules at LOW and HIGH concentrations remained higher than a 90% threshold of concentration, indicating the mixture was chemically stable. Degradation rates of bumetanide and scopolamine content at LOW and HIGH concentrations should not exceed a maximum of 0.70% every 10 days. This study was the first to show that the admixture of bumetanide and scopolamine is physically and chemically stable at two concentrations used in a palliative-care unit. This combination available in ready-to-use polypropylene syringes presents numerous advantages for patient’s comfort and safety.
Related Keywords:
bumetanide, loop diuretic, scopolamine, anticholinergic agent, drug combination, drug admixture, death rattle, secretions, pulmonary fluid overload, end of life, terminal life stage, palliative care, physical stability, chemical stability, compatibility
Related Categories:
PARENTERALS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, STERILE PREPARATIONS, HOSPITAL PHARMACY, RESPIRATION/LUNG/BREATHING
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine
Catry Emilie, Colsoul Marie-Louise, Closset Melanie, Hubert Justine, Soumoy Laura, Bihin Benoit, Thiry Emmanuell, Jamart Jacques, Hecq Jean-Daniel, Galanti Laurence
|
May/Jun 2022
Pg. 248-254
|
Chemical Stability of Scopolamine Hydrobromide Nasal Solution
Gupta Vishnu D
|
Sep/Oct 2009
Pg. 438-439
|
Bumetanide 0.5-mg, 1-mg, or 2-mg Capsules
Allen Loyd V Jr
|
May/Jun 2014
Pg. 233
|
Bumetanide 0.25-mg/mL Injection
Allen Loyd V Jr
|
Jan/Feb 2014
Pg. 61
|
Wetting and/or Solubilizing Agents, Featured Excipient:
Allen Loyd V Jr
|
Jul/Aug 2001
Pg. 310-312
|
Physicochemical Stability and Compatibility of Revefenacin (LAMA) and Formoterol Fumarate (LABA) Inhalation Solution Admixture
Ngim Kenley, Patel Jalpa
|
May/Jun 2020
Pg. 242-245
|
Intravenous Admixture Preparation Considerations, Part 7: Stability Issues
Allen Loyd V Jr
|
Nov/Dec 2020
Pg. 473-478
|
Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions
Wilder Alyson G, Foushee Jaime A, Fox Laura M, Navalle Jordan, Wright Adrienne M, Greer Megan A
|
May/Jun 2020
Pg. 238-241
|
Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline
Klemmer Anja, Krämer Irene, Kamin Wolfgang
|
May/Jun 2013
Pg. 254-261
|
Quality Control Analytical Methods: End-preparation Assessments and Tests for Compounded Sterile Preparations
McElhiney Linda F
|
Jul/Aug 2013
Pg. 307-311
|
Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Dillon L R
|
Jan/Feb 2020
Pg. 30-36
|
Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved
Allen Loyd V Jr
|
Jan/Feb 2020
Pg. 44-50
|
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
|
Sep/Oct 2017
Pg. 356
|
Intravenous Admixture Preparation Considerations, Part 9-B: Error Prevention in Intravenous Admixture Preparation
Allen Loyd V Jr
|
May/Jun 2021
Pg. 222-229
|
Intravenous Physical Compatibility of Heparin Sodium and Furosemide
Maktabi Briana, Howard Mitchell S, Baki Gabriella, Churchwell Mariann D
|
Nov/Dec 2022
Pg. 522-526
|
Intravenous Admixture Preparation Considerations, Part 9-A: Error Prevention in Intravenous Admixture Preparation
Allen Loyd V Jr
|
Mar/Apr 2021
Pg. 131-139
|
Scopolamine Hydrobromide 0.25% Ophthalmic Solution
Allen Loyd V Jr
|
Jul/Aug 2016
Pg. 326
|
Chemical Stability of Morphine, Ropivacaine, and Ziconotide in Combination for Intrathecal Analgesia
Robert Julien, Sorrieul Jérémy, Rossignol Elsa, Beaussart Hélène, Kieffer Hélène, Folliard Caroline, Dupoiron Denis, Devys Catherine
|
Jul/Aug 2017
Pg. 347-351
|
Alcohol-free Extemporaneous Formulations of Furosemide Are Chemically and Physically Stable in Ora-Blend Products for 30 Days
Svirskis Darren, Jaffer Johaina, Agarwal Priyanka, Khan Ayeshah, Kaur Jaskarn, Cheng Alan, Hanning Sara
|
May/Jun 2020
Pg. 246-251
|
Intravenous Admixture Preparation Considerations, Part 8: Ready-to-Use Preparations
Allen Loyd V Jr
|
Jan/Feb 2021
Pg. 31-38
|
Return to Top |